Therapy Areas: Oncology
Tempus agrees to acquire Personalis in USD1.5bn precision oncology deal
20 July 2026 - Personalis Inc (Nasdaq: PSNL), a provider of advanced genomics for precision oncology, announced on Monday that it has agreed to be acquired by technology firm Tempus AI Inc (NASDAQ: TE...
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
20 July 2026 - Evaxion A/S, a Denmark-based, clinical-stage TechBio company developing novel vaccines with its AI-Immunology platform, said on Friday that it will present three-year clinical efficacy ...
Ananda Pharma doses first patient in MRX1 clinical trial of patients with chemotherapy induced peripheral neuropathy
20 July 2026 - UK biopharmaceutical company Ananda Pharma Limited announced on Friday that the first patient taking part in the ACTiON clinical trial investigating the efficacy of MRX1, Ananda's ...
Raidium introduces AI-powered oncology imaging workflow for US cancer centres
17 July 2026 - AI-native radiology company Raidium announced on Thursday the US launch of Raidium Read (R.Read), applying its AI-native imaging solution initially to oncology research centres.Raidium ...
Galmed announces breakthrough development of SCD1 inhibitor Aramchol for cardiac fibrosis
17 July 2026 - Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and gastrointestinal oncology, announced on Thursday the breakthro...
Intensity Therapeutics restarts breast cancer Phase 2 clinical trial
16 July 2026 - Intensity Therapeutics Inc (Nasdaq:INTS), a late-stage clinical biotechnology company, announced on Wednesday that new patients have been administered INT230-6 in the INVINCIBLE-4 Study...